Moderna, known for its COVID-19 vaccine, saw its stock rise by 1,226.9% between 2020 and 2022. With vaccine demand decreasing post-pandemic, investors are curious if Moderna can diversify and sustain growth beyond COVID-19. The company’s revenue dropped by 35.3% in Q1 of 2025 due to lower product sales, impacting investors. Moderna’s RSV vaccine mRESVIA generated $2 million in sales in the first quarter, while a combined COVID-19/flu vaccine is in phase 3 trials. Despite revenue challenges, the company is investing in R&D for future vaccine developments. Analysts are mixed on Moderna stock, with an average target price suggesting potential for a 30% rally.

Read more at Yahoo Finance: 1 Analyst Thinks This Former Pandemic Winner Could Surge 500% This Year